Coordinated regulation using small-molecule drugs enables controlled therapeutic genome editing and enhanced genomic precision in situ.
Precisely controlled gene editing in mice safely corrected two serious diseases with minimal off-target DNA damage, advancing therapeutic potential.
The PRINCE and Little Prince small-molecule-inducible genome editing platforms demonstrate temporal control over CRISPR-Cas9 and prime editing with dramatically reduced off-target activity compared to constitutive editors, including sustained 2-year precision in human cell cultures. In humanized mouse models, single-AAV delivery achieved meaningful therapeutic correction of hypercholesterolemia and neovascular AMD, positioning these systems as the most precisely controlled in vivo genome editing platforms reported to date.
What the study was
- Study design
- Preclinical (in vitro + humanized mouse model) proof-of-concept
- Population
- Humanized mouse models for hypercholesterolemia and neovascular AMD; human cell cultures
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Science Translational Medicine
Why it surfaced
Genuinely novel controlled-inducible genome editing with dramatically reduced off-target events and in vivo therapeutic correction in two rare disease models (hypercholesterolemia, AMD). Published in Sci Transl Med. Score capped at 5 per non-human/mixed species rule. NOVEL_TREATMENT flag auto-elevates to HIGH. No human data yet.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.